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Abstract
Airway smooth muscle cells exhibit phenotype plasticity that underpins their ability to contribute both to acute bronchospasm and to
the features of airway remodelling in chronic asthma. A feature of mature, contractile smooth muscle cells is the presence of abundant
caveolae, plasma membrane invaginations that develop from the association of lipid rafts with caveolin-1, but the functional role of cave-
olae and caveolin-1 in smooth muscle phenotype plasticity is unknown. Here, we report a key role for caveolin-1 in promoting pheno-
type maturation of differentiated airway smooth muscle induced by transforming growth factor (TGF)-1. As assessed by Western analy-
sis and laser scanning cytometry, caveolin-1 protein expression was selectively enriched in contractile phenotype airway myocytes.
Treatment with TGF-1 induced profound increases in the contractile phenotype markers sm--actin and calponin in cells that also accu-
mulated abundant caveolin-1; however, siRNA or shRNAi inhibition of caveolin-1 expression largely prevented the induction of these
contractile phenotype marker proteins by TGF-1. The failure by TGF-1 to adequately induce the expression of these smooth muscle spe-
cific proteins was accompanied by a strongly impaired induction of eukaryotic initiation factor-4E binding protein(4E-BP)1 phosphory-
lation with caveolin-1 knockdown, indicating that caveolin-1 expression promotes TGF-1 signalling associated with myocyte matura-
tion and hypertrophy. Furthermore, we observed increased expression of caveolin-1 within the airway smooth muscle bundle of guinea
pigs repeatedly challenged with allergen, which was associated with increased contractile protein expression, thus providing in vivo evi-
dence linking caveolin-1 expression with accumulation of contractile phenotype myocytes. Collectively, we identify a new function for cave-
olin-1 in controlling smooth muscle phenotype; this mechanism could contribute to allergic asthma.
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Introduction
Smooth muscle cells regulate the diameter of hollow organs and
are effectors of fibroproliferative remodelling in several disease
states. In this regard, bronchial smooth muscle cells regulate air-
way diameter and play a key role in lung function and airway
hyperresponsiveness in asthma [1]. Structural and phenotypic
alterations in airway smooth muscle are frequently observed in
asthma and include increased airway smooth muscle mass and
increased abundance of contractile phenotype marker proteins.
Phenotype plasticity of airway smooth muscle is regulated by
external stimuli such as growth factors (e.g. transforming growth
factor [TGF]-1) and the extracellular matrix, that signal through a
network of intracellular cascades to control the transcription and
translation of smooth muscle-specific genes [2–4].
A feature of mature, contractile airway smooth muscle is the
presence of abundant caveolae, plasma membrane invaginations
that regulate a variety of physiological functions including
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myocyte contraction and cell proliferation [5–8]. Caveolae in
smooth muscle are characterized by the presence of caveolin-1
and caveolin-2 [9] as well as the more recently described cavin
family members including polymerase I and transcript release fac-
tor (PTRF)/cavin-1 [10, 11]. Caveolin-1 and cavin-1 interact at the
plasma membrane which is required for caveola formation [10].
Caveolae exhibit a highly ordered linear array distribution on con-
tractile smooth muscle cells; this because of indirect tethering to
the actin cytoskeleton via direct binding of caveolin-1 to -dystro-
glycan, which is also a contractile phenotype marker protein
[12–15]. Increased caveolin-1 and caveolae abundance in mature
myocytes likely maintains a mitotically quiescent phenotype, as
disruption of caveolae, or caveolin-1 knockdown is sufficient to
activate p42/p44 MAP kinase signalling and cell proliferation [6].
Caveolin-1 functionally represses myocyte proliferation via its
caveolin scaffolding domain that binds to (receptor) tyrosine
kinases (RTKs), such as epidermal growth factor receptor,
platelet-derived growth factor receptor and Src [16–19]. The asso-
ciation of RTK with caveolae and caveolin-1 in airway smooth
muscle is reversible, as mitogen stimulation induces the release of
caveolin-1 from the activated RTK which facilitates RTK trafficking
to non-caveolae membrane [6, 20]. Caveolin-1 thus plays an
important role in maintaining airway myocyte quiescent, which is
a hallmark of contractile phenotype cells.
The functional role of increased caveolae and caveolin-1 in
contractile phenotype smooth muscle cells is not fully established.
It may support molecular signalling associated with contraction,
as for most smooth muscles, disruption of caveolae or caveolin-1
knockdown is sufficient to reduce agonist-induced Ca2
responses and contraction [5, 7, 8, 21–28]. Indeed, airway
smooth muscle contraction and Ca2 signalling in response to the
bronchoconstrictor agents methacholine, histamine and
bradykinin requires intact caveolae, and the receptors and G pro-
teins that regulate contraction in response to these agents are
localized to caveolae [5, 7, 8]. In addition, a recent study indicates
that the expression of dystrophin, -dystroglycan, -, - and -
sarcoglycan, which localize to caveolae in airway smooth muscle,
is tightly correlated with the expression of contractile phenotype
markers and caveolin-1 [14, 15]. Although these studies collec-
tively suggest a functional role for elevated caveolin-1 abundance
in the contractile myocyte phenotype, the requirement for cave-
olin-1 in the acquisition of a contractile phenotype has not yet
been explored.
Phenotype plasticity and heterogeneity of airway smooth mus-
cle may contribute to asthma pathogenesis as asthmatic airway
smooth muscle is characterized by increased expression of con-
tractile proteins including sm--actin, myosin heavy chain (sm-
MHC), SM-22 and myosin light chain kinase, and is associated
with divergent cellular functions [29–35]. Alterations in airway
smooth muscle mass and in contractile protein expression are
also seen in animal models of asthma including the guinea pig,
which is characterized by increased bronchial and bronchiolar
smooth muscle mass and elevated expression of smooth muscle
specific proteins such as sm-MHC. Although phenotype plasticity
of airway smooth muscle involves regulation of caveolin-1 and
caveolae expression in vitro, it is currently unknown whether reg-
ulation of caveolin-1 expression by airway smooth muscle is also
a feature of airways disease and whether this may be linked with
regulation of airway smooth muscle phenotype and function in the
remodelled airway wall.
We suggested that the phenotype-dependent expression of
caveolin-1 expression directly supports mycocyte maturation by
regulating and facilitating cellular signalling involved in smooth
muscle specific protein expression and that such a mechanism
contributes to airway smooth muscle remodelling in asthma.
Using human airway smooth muscle cell lines, and caveolin-1
knockdown strategies, we demonstrate that caveolin-1 is required
for TGF-1-induced myocyte maturation. Moreover, we confirm in
vivo using allergen challenged guinea pigs that caveolin-1 expres-




Canine and human airway smooth muscle cells were used for cell culture
studies. Primary cultured canine airway myocytes were established from
dissociated canine trachealis as we have described previously [36, 37].
Human bronchial smooth muscle cell lines immortalized by stable expres-
sion of human telomerase reverse transcriptase were prepared as
described previously [6, 38]. The primary cultured human bronchial
smooth muscle cells used to generate human telomerase reverse tran-
scriptase airway smooth muscle cells were prepared from macroscopically
healthy segments of second-to-fourth generation main bronchus obtained
after lung resection surgery from patients with a diagnosis of adenocarci-
noma. All procedures were approved by the Human Research Ethics Board
(University of Manitoba, Winnipeg, MB, Canada).
Cells were grown to confluence using Dulbecco’s modified eagle
medium (DMEM) supplemented with 10% foetal bovine serum, 50 U/ml
streptomycin and 50 g/ml penicillin. Cultures were maintained in a
humidified incubator at 37C/5% CO2 and media were changed every 2–3
days. For the induction of contractile phenotype myocytes serum-depriva-
tion protocols were used (Fig. 1): confluent cultures of canine (passage
number 0 or 1) or human airway smooth muscle cell (passages 10–25)
were maintained in Ham’s F12 medium supplemented with 5 g/ml insulin,
5 g/ml transferrin and 5 ng/ml selenium (ITS) for 7–14 days. For the
induction of contractile phenotype with TGF-1 cultures were serum-
deprived for 2 days in ITS-supplemented Hams F12 media then cells were
switched to fresh media supplemented only with TGF-1 (0.1–10 ng/ml),
for 2, 4 or 7 days.
Western blot analysis
Protein content in samples was determined using the Bio-Rad protein
assay with bovine serum albumin as a reference (Bio-Rad, Hercules, CA,
USA). Equal amounts of protein from total protein lysates were subjected
to electrophoresis, transferred to nitrocellulose membranes and analysed
2432 © 2011 The Authors
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Fig. 1 Preferential expression of 
caveolin-1 by contractile phenotype 
airway myocytes. (A) Human airway
smooth muscle cell cultures were
grown to 50% confluence in serum-
enriched (10% FBS) DMEM (serum-fed
condition) or grown to confluence and
then serum deprived in Ham’s F12 sup-
plemented with ITS (serum-deprived
condition) for 7 days. Cell lysates were
prepared and analysed by immunoblot-
ting for the abundance of caveolin-1,
sm-MHC and -actin. Densitometric
data shown are the means 	 S.E. of
four experiments. Differences between
data were analysed by a two-tailed
Student’s t-test for unpaired observa-
tions; *P 
 0.05. (B) Primary human
(left row) and canine (right row) tra-
cheal smooth muscle cells were grown
to confluence on cover slips and then
serum-deprived for 14 days in Ham’s
F12 supplemented with ITS. After fixa-
tion cells were dually immunolabelled
for sm-MHC (red Cy3; upper row) and
caveolin-1 (green FITC; lower row). For
the images shown, nuclei of human
cells were also labelled with the DNA
dye H33342 (blue). Micrographs in
each row are matched fields and
arrows are drawn for orientation and to
highlight elongate, contractile pheno-
type myocytes. (C) Left panel shows a
typical image captured by laser scan-
ning cytometry of sm-MHC staining
(red) of in a 14-day serum deprived
canine tracheal myocyte culture. The
image is shown with an overlay of the
phantom contour lattice (yellow cir-
cles) used to identify regions of interest
in which integrated fluorescence of
both sm-MHC and caveolin-1 (green)
were determined. After determining
background fluorescence each region
was classified as either sm-MHC– (flu-
orescence equal to or less than back-
ground) or sm-MHC (fluorescence
greater than background fluorescence).
The right panel shows the results of
measuring coincident caveolin-1 and
sm-MHC staining in 1054 contour
regions of interest in five scan fields for
three different cell cultures. Differences
in mean integrated fluorescence
between sm-MHC and sm-MHC–
groups were analysed by a two-tailed
Student’s t-test for unpaired observa-
tions; *P 
 0.001.
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for the proteins of interest using specific primary and horseradish peroxi-
dase (HRP)-conjugated secondary antibodies. Bands were subsequently
visualized on film using enhanced chemiluminescence reagents and were
quantified by densitometry using TotallabTM software (Nonlinear dynamics;
Newcastle, UK). Expression of proteins of interest was normalized to the
expression of -actin.
Immunocytochemistry
Airway smooth muscle cells were plated onto pre-cleared glass cover slips
in six-well culture dishes. Cells were fixed for 15 min. at 4C in cytoskeletal
buffer [10 mM 2-(N-morpholino)ethanesulfonic acid (MES), 150 mM NaCl,
5 mM glycol-bis(2-aminoethylether)-N,N,N,N-tetraacetic acid (EGTA), 
5 mM MgCl2 and 5 mM glucose at pH 6.1] containing 3% paraformalde-
hyde. Cells were then permeabilized by incubation for 5 min. at 4C in
cytoskeletal buffer containing 3% paraformaldehyde and 0.3% Triton X-
100. For immunofluorescence microscopy, fixed cells were first blocked
for 2 hrs at room temperature in Cyto-Tris-buffered saline (TBS) buffer 
(20 mM Tris base, 154 mM NaCl, 20 mM EGTA and 20 mM MgCl2 at pH
7.2) containing 1% bovine serum albumin and 2% normal donkey serum.
Incubation with primary antibodies occurred overnight at 4C in Cyto-TBS
containing 0.1% Tween 20 (Cyto-TBST). Incubation with FITC- or Cy5-
conjugated secondary antibodies was for 2 hrs at room temperature in
Cyto-TBST. Nuclei were stained with Hoechst 33342 (10 g/ml).
Fluorescence micrographs of stained cells were then obtained using an
inverted Fluoview Confocal Microscope (Olympus, Markham, ON, Canada).
Laser scanning cytometry
For quantitative assessment of the of co-expression of caveolin-1 and sm-
MHC of individual cells of serum deprived cultures, fluorescent labelling in
dual-labelled cultures (as described in ‘Immunocytochemistry’) as meas-
ured using an inverted microscope-based iCys Research Laser Scanning
Cytometer (CompuCyte Corp., Cambridge MA, USA). For analysis fluores-
cent images acquired with calibrated photomultiplier tubes were overlaid
with a lattice of 1054 circular contours (regions of interest) that enable
comprehensive sampling of the entire scanned fields; the diameter of each
contour was 5 M, thus was approximately equivalent to the minimum
width of individual nuclei. From the contour lattice integrated fluorescence,
after background adjustment, of both sm-MHC (red) and caveolin-1
(green) in each region of interest was determined. Coincident staining of
caveolin-1 and sm-MHC in each contour was determined in at least five
scan fields for three different cell cultures for analyses.
siRNA transfection
The small interfering RNA (siRNA) Generation Kit (Gene Therapy Systems,
San Diego, CA, UDA) was used to prepare dicer-generated siRNA from
human airway smooth muscle cDNA as we have described previously [38]
with primers that amplified caveolin-1 (forward 5-GTAGACTCGGAGGGA-
CATC-3; reverse 5-GTCCGCATCAACTTGCAG-3). Primer sequences also
included the 52-bp T7 promoter sequence linkers (5-GCGTAATACGACT-
CACTATAGGGAGA-target DNA-3), which were incorporated into the DNA
template PCR product to allow for in vitro transcription with the
TurboScript T7 Transcription Kit (Gene Therapy Systems). Double-
stranded RNA was generated using the TurboScript T7 RNA Transcription
Kit and then diced into 21 bp fragments using recombinant human dicer
enzyme following the manufacturer’s instructions (Gene Therapy
Systems). Transfection of siRNA (1 g/ml) was performed with
Genesilencer reagent (Gene Therapy Systems) according to manufac-
turer’s instructions, and cells were maintained in serum-free Ham’s F12
thereafter. For negative control studies the transfection protocol was per-
formed in the absence of siRNA.
In separate studies, caveolin-1 knockdown was achieved using a com-
mercially available 21 bp, double-stranded siRNA targeted against a sequence
between residues 529 and 589 of the caveolin-1 transcript (Qiagen,
Mississauga, ON, Canada). Transfection to suppress caveolin-1 protein
expression was carried out as we have previously described [6, 7, 38]. Cells
were transfected using 2.5 g/ml of siRNA in combination with 6 l/g
siRNA of RNAiFectTM transfection reagent (Qiagen). For negative control
studies the transfection protocol was performed in the absence of siRNA.
As a third strategy we used to constitutively silence caveolin-1, human
airway smooth muscle were infected with lentivirus harbouring short hair-
pin RNA directed against caveolin-1 and after selection with puromycin,
cell lines that stably express caveolin-1 short hairpin (sh)RNA were estab-
lished as we have described [39]. shRNA containing constructs were from
Open Biosystems distributed by the Manitoba Centre for Systems Biology
and Proteomics at the University of Manitoba. The caveolin-1 shRNA con-
struct (accession #NM_001172897), distributed in a bacterial culture of
Escherichia coli (DH5) included a ‘stem’ of 21 sense (GAGGGTCCTGTA-
CAATCTCAT), antisense base pairs, and a 6 bp loop, cloned into the lentiviral
vector pGIPZ. Individual colonies were grown up in Luria-Bertani (LB) broth
with ampicillin (100 g/ml), purified using a Qiagen Maxi-prep Kit. A vesic-
ular stomatitis virus G(VSVG) pseudo-typed lentiviral vector was made
using human embryonic kidney (HEK) 293T cells by calcium phosphate
transfection of purified caveolin-1 shRNA plasmid, virus packaging vector
(8.2vpr), and a VSVG plasmid as described previously [40]. Primary
human airway myocytes were grown to 70% confluence and transduced at
a multiplicity of infection (MOI) of 6, in the presence of 8 g/ml polybrene,
for 2 hrs. Excess viral particles were removed, and the transduced cells
were cultured in fresh medium for 2 days. Cell cultures exhibiting stable
expression of the shRNA (Cav-1silence) were selected by growing in culture
media containing puromycin (4 g/ml) for 3 weeks. For control cells (Cav-
1scramble) a pGIPZ vector harbouring ‘scrambled’ non-coding shRNA was
also prepared and used to generate lentivirus for transduction of the same
primary human airway smooth muscle (HASM) cell lines that were used to
generate caveolin-1-silenced stable cultures.
Guinea pig asthma model
Outbred, male, specified pathogen free Dunkin Hartley guinea pigs (Harlan,
Heathfield, UK) weighing 250–300 g were sensitized to ovalbumin using
Al(OH)3 as adjuvant. The animals were used experimentally 4 weeks later.
All protocols described in this study were approved by the University of
Groningen Committee for Animal Experimentation. Provocations were per-
formed by inhalation of aerosolized solutions of ovalbumin (Sigma, St.
Louis, MO, USA) or saline under conscious and unrestrained conditions,
as described previously [41]. Allergen inhalations were discontinued when
the first signs of respiratory distress were observed. No anti-histaminic
was needed to prevent anaphylactic shock. Guinea pigs were challenged
with either ovalbumin or saline once weekly, for 12 consecutive weeks, to
induce airway remodelling as described previously [42, 43]. Twenty-four
hours after the last challenge, guinea pigs were killed by experimental con-
cussion, followed by rapid exsanguination. The lungs were immediately
resected and kept on ice for further processing.
2434
Histochemistry
Transverse cross-sections of the main bronchi in both right and left lung
lobes were used for immunohistochemical analysis of caveolin-1. Sections
were blocked using 0.3% hydrogen peroxide and stained using a poly-
clonal anti-caveolin-1 antibody (SantaCruz Biotechnology, Santa Cruz, CA,
USA). The primary antibody was visualised using a HRP-linked secondary
antibody and diaminobenzidine. Airways within sections were digitally pho-
tographed. All immunohistochemical measurements were carried out dig-
itally using quantification software.
Materials
Cell culture media (DMEM and Ham’s F12), supplements (foetal bovine
serum and ITS-A) and antibiotics (penicillin and streptomycin) were
obtained from Invitrogen (Carlsbad, CA, USA). Caveolin-1 monoclonal 
antibody was from BD Biosciences (San Jose, CA, USA) and polyclonal anti-
body from SantaCruz Biotechnology. Fluorescein isothiocyanate (FITC)- and
Cy5-conjugated secondary antibodies were from Jackson ImmunoResearch
(West Grove, PA, USA). Recombinant human TGF-1, -actin primary anti-
body, sm--actin primary antibody, sm-MHC primary antibody, calponin
primary antibody anti-rabbit and antimouse HRP conjugated secondary
antibodies, were from Sigma-Aldrich (St. Louis, MO, USA). Anti-phospho-
Thr37/46–4E-BP1 primary antibody and anti-4E-BP1 primary antibody were
all from Cell Signaling Technology (Beverly, MA, USA). Enhanced chemilu-
minescence reagent was from Amersham (Oakville, ON, Canada).
Results
Caveolin-1 is preferentially expressed 
by contractile phenotype airway myocytes
We previously reported that proliferating human airway smooth
muscle cells in culture express reduced levels of caveolin-1 pro-
tein [6]. We first confirmed the preferential expression of caveolin-
1 in cell culture conditions that promote acquisition of a contrac-
tile phenotype that is characterized by enhanced expression of
marker proteins such as sm-MHC, sm--actin and calponin [44].
Immunoblot analysis of caveolin-1 abundance in 7 day serum
deprived human airway smooth muscle cultures revealed it was
increased approximately 2-fold compared to myocytes in prolifer-
ating cultures (Fig. 1A). This paralleled the accumulation of sm-
MHC in the same cultures, thus revealing correlation between the
expression of contractile phenotype markers and caveolin-1 by
human airway smooth muscle cells.
To more precisely assess caveolin-1 and sm-MHC expression in
individual myocytes we employed serum-deprived primary cul-
tured human airway and canine tracheal smooth muscle. Confocal
microscopy of dually labelled human and canine myocyte cultures
reveal divergent labelling of individual cells for sm-MHC, and this
pattern appeared to be mimicked by that for caveolin-1 (Fig. 1B).
To quantify the degree to which caveolin-1 was co-expressed in
individual cells we next used laser scanning cytometry of 7 day
serum-deprived canine tracheal myocyte cultures. We selected this
culture system for analysis because we have shown it to be a
unique and effective model to study myocyte phenotype switching
using microscopy because it retains a monolayer organization and
two disparate subpopulations develop that differ markedly in
morphological and phenotypic features [36]. As confirmed in 
Figure 1B, a large fraction of cells exhibit a relatively small, flat
oblong shape and are devoid of contractile proteins, whereas 
the remaining myocytes develop tracks of cells having an elongate
hypertrophic morphology that are uniquely enriched in contractile
phenotype markers, including sm-MHC and sm--actin [35]. Our
laser scanning cytometry analysis clearly demonstrated caveolin-1
expression was selectively enriched in those myocytes that accu-
mulated sm-MHC in serum free conditions, whereas in myocytes
that were essentially sm-MHC– based on fluorescent staining,
caveolin-1 was low and significantly less that in sm-MHC-rich cells
(Fig. 1C). This confirms that abundant caveolin-1 expression is a
specific feature of mature, contractile airway smooth muscle.
TGF-1-induced contractile protein expression 
by airway smooth muscle requires caveolin-1
We next tested the functional significance of the increased expres-
sion of caveolin-1 by mature airway smooth muscle for the induc-
tion of contractile protein expression. To investigate this, we used
the growth factor TGF-1, which induces the expression of con-
tractile phenotype marker proteins in primary human airway
smooth muscle cells [45]. In addition, autocrine production of
TGF-1 has been reported to be responsible for the serum-
deprivation induced phenotype maturation of airway smooth mus-
cle cells in culture [46]. We first established the functional effects
of TGF-1 on contractile protein expression by the human airway
smooth muscle cell lines. In these protocols, cells were grown to
confluence and then serum-deprived in the absence or presence
of TGF-1 for 2, 4 or 7 days. As reported for primary myocytes,
TGF-1 induced a profound increase in the expression of the con-
tractile phenotype markers sm--actin and calponin (Fig. 2). The
induction of these marker proteins was clearly visible after 2 days
of TGF-1 exposure, although 4 and 7 days of exposure did fur-
ther increase sm--actin and calponin expression (e.g. calponin
expression induced by TGF-1 on days 4 and 7 was 125 	 19%
and 124 	 31% of that measured after 2 days of TGF-1 expo-
sure; Fig. 2A). Concentration response relationships of TGF-1
after 2 days of treatment indicated that the induction of calponin
and sm--actin expression was submaximal at a concentration of
1 ng/ml (Fig. 2B–D). Notably, TGF-1 treatment did not augment
spontaneously increased caveolin-1 expression during serum
deprivation at any of the time-points or concentrations studied
(Fig. 2E). Because 2 days of TGF-1 treatment with 1 ng/ml was
found to induce sub-maximal induction of contractile protein
expression, this condition was used in all further experiments.
© 2011 The Authors
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To investigate whether caveolin-1 expression by airway
smooth muscle was required for contractile phenotype maturation
induced by TGF-1, we next employed an siRNA knockdown strat-
egy to reduce caveolin-1 expression. Initial experiments indicated
that caveolin-1 expression was clearly reduced by siRNA treat-
ment 48 hrs after transfection with maximal reduction of ~50%
being reached at 72 hrs (Fig. 3A, [6, 7]). Notably, this reduction in
caveolin-1 expression is quantitatively similar in magnitude to the
opposing increase in caveolin-1 expression that we observe when
proliferating myocytes are subjected to prolonged serum with-
drawal (Fig. 1A). Indeed we previously reported that this level of
caveolin-1 silencing is sufficient to promote spontaneous p42/p44
MAP kinase activation and cell proliferation of airway smooth
muscle cells [6]. To utilize the window of caveolin-1 knockdown
optimally, we transfected airway smooth muscle cells with 
caveolin-1 siRNA and 48 hrs thereafter stimulated them with 
TGF-1. Cell lysates were harvested 48 hrs later (96 hrs after
transfection). Three distinct knockdown strategies were
employed: (1) a commercially available siRNA directed against a
single sequence of the caveolin-1 transcript, (2) a dicer-generated
siRNA mix, produced from a 537 bp sequence within the caveolin-1
transcript digested using recombinant dicer enzyme and (3) stable
silencing using shRNAi delivered by lentivirus infection to generate
Cav-1silence human airway smooth muscle cell lines. We confirmed
that both the siRNA and shRNA strategies did not impair smooth
muscle cell viability. In fact, cell proliferation and ERK activation
were enhanced by the caveolin-1 knockdown ([6] and unpublished
observations).
Both the commercially available siRNA and the dicer-
generated siRNA mix strongly reduced the potential for TGF-1 to
Fig. 2 TGF-1 induces contractile phenotype marker expression in airway smooth muscle. (A) Human airway smooth muscle cells were grown to conflu-
ence, serum-deprived for 2 days and subsequently treated for 2, 4 or 7 days in F-12 media with 10 ng/ml TGF-1, as indicated. Cell lysates were then
prepared and Western analysed for the expression of sm--actin, calponin, caveolin-1 or -actin. (B) Human airway smooth muscle cells were grown to
confluence, serum-deprived for 2 days in F-12 media, followed by 2 days treatment w increasing concentrations (0.1–10 ng/ml) of TGF-1, as indicated.
Cell lysates were then prepared and analysed by Western blot for the expression of sm--actin, calponin, caveolin-1 or -actin. Expression of (C) sm--
actin, (D) calponin and (E) caveolin-1 was also analysed by densitometry and normalized to the maximal response induced by TGF-1, which was set at
100%. -actin expression was used to correct for small differences in protein loading.
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induce contractile phenotype marker expression by airway smooth
muscle (Fig. 3). The reduction in marker expression by the com-
mercially available caveolin-1 siRNA was profound, particularly for
sm--actin, and the reduction in marker expression induced by the
dicer-generated siRNA was almost complete. These data indicate a
requirement for increased expression of caveolin-1 in TGF-1
induced contractile protein accumulation. Baseline expression of
marker proteins also appeared to be reduced by the caveolin-1
siRNA in some conditions, but this effect did not reach statistical
significance.
We next investigated whether reduced induction of contractile
phenotype marker expression was associated with a change in
TGF-1 induced intracellular signalling. TGF-1 activates phos-
phatidylinositol-3-kinase signalling, which leads to the phospho-
rylation of 4E-BP1. 4E-BP1 phosphorylation releases its inhibitory
function to facilitate protein translation, which is required for air-
way smooth muscle hypertrophy and phenotype maturation
induced by TGF-1 [37, 47, 48]. Indeed, TGF-1 induced the 
phosphorylation of 4E-BP1 in a concentration dependent manner
(Fig. 4A). Interestingly, caveolin-1 knockdown using either the
Fig. 3 Caveolin-1 knockdown reduces TGF-1 induced contractile phenotype marker expression. (A) Human airway smooth muscle cells were grown
to 70–80% confluence and then serum-deprived in F-12 media. Concomitant with serum-deprivation, cells were transfected with an siRNA directed
against caveolin-1 and maintained in culture for up to 4 days. Cell lysates were then prepared and analysed for caveolin-1 and -actin content. (B)
Human airway smooth muscle cells were grown to 70–80% confluence and then serum-deprived in F-12 media for 2 days. Concomitant with serum-
deprivation, cells were transfected with either a commercially available siRNA directed against caveolin-1 or a dicer-generated siRNA mix directed
against caveolin-1. Cells treated with transfection reagent alone served as controls (vehicle). Caveolin-1 knockdown was allowed to occur for 2 days
in serum-free F-12 media, after which cells were treated with TGF-1 (1 or 10 ng/ml, as indicated) for another 2 days. Cell lysates were then pre-
pared and analysed for sm--actin, calponin and -actin content. Expression of (C) sm--actin and (D) calponin was analysed by densitometry and
normalized to the maximal response induced by TGF-1, which was set at 100%. -actin expression was used to correct for small differences in
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commercially available or the dicer-generated siRNA strongly
reduced, or even abrogated the capacity for TGF-1 to induce 4E-
BP1 phosphorylation, suggesting that this mechanism is in part
responsible for the observed effects on calponin and sm--actin
expression (Fig. 4B and C). These results were confirmed using
the Cav-1silence human airway smooth muscle cell line that exhibits
60% reduced expression of caveolin-1 protein. Our findings
show that constitutive suppression of caveolin-1 expression
markedly limits capacity for TGF-1-induction of sm--actin
expression and 4E-BP1 phosphorylation (Fig. 4D).
Fig. 4 Caveolin-1 knockdown reduces TGF-1 induced 4EBP-1 phosphorylation. (A) Human airway smooth muscle cells were grown to confluence and
subsequently serum-deprived for 2 days in F-12 media in the absence or presence of increasing concentrations (0.1–10 ng/ml) of TGF-1, as indicated.
Cell lysates were then prepared and Western analysed for the expression of phospho-(Thr37/46)-4E-BP-1, total 4E-BP-1 and -actin content. (B) Human
airway smooth muscle cells were grown to 70–80% confluence and then serum-deprived in F-12 media for 2 days. Concomitant with serum-deprivation,
cells were transfected with a dicer-generated siRNA mix directed against caveolin-1. Cells treated with transfection reagent alone served as controls (vehi-
cle). Caveolin-1 knockdown was allowed to occur for 2 days in serum-free F-12 media, after which cells were treated with TGF-1 (1 ng/ml) for another
2 days. Cell lysates were then prepared and analysed for phospho-(Thr37/46)-4E-BP-1, total 4E-BP-1 and -actin content. (C) Human airway smooth
muscle cells were grown to 70–80% confluence and then serum-deprived in F-12 media for 2 days. Cells were transfected with either a commercially
available siRNA directed against caveolin-1 or a dicer-generated siRNA directed against caveolin-1. Cells treated with transfection reagent alone served
as controls (vehicle). Caveolin-1 knockdown was allowed to occur for 2 days in serum-free F-12 media, after which cells were treated with TGF-1 (1 or
10 ng/ml, as indicated) for another 2 days. Cell lysates were then prepared and analysed for phospho-(Thr37/46)-4E-BP-1, total 4E-BP-1 and -actin con-
tent. Expression of phospho-(Thr37/46)-4E-BP-1 was analysed by densitometry and normalized to the maximal response induced by TGF-1, which was
set at 100%. -actin expression was used to correct for small differences in protein loading. Differences between data were analysed by two-way ANOVA,
with post hoc Bonferroni’s t-test for multiple comparisons. *P 
 0.05; **P 
 0.01; ***P 
 0.001. (D) Human airway smooth muscle cell lines (Cav-
1silence) stably expressing shRNA against caveolin-1, and Cav-1scramble, which stably express a control, non-coding shRNA were treated for 48 hrs with
TGF-1 (1 ng/ml). Cell lysates were prepared and analysed for the proteins of interest using Western blotting.
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Caveolin-1 expression is increased in smooth
muscle after allergen challenge in guinea pigs
Our current results and published data [6–8] indicate a role for
caveolin-1 in contractile function and contractile phenotype matu-
ration of airway smooth muscle. Increased contraction of smooth
muscle, and increased expression of contractile phenotype mark-
ers are characteristic for asthma, and can be mimicked in animal
models of asthma [43]. Guinea pigs repeatedly challenged with
ovalbumin develop airway hyperresponsiveness, airway smooth
muscle thickening, increased pulmonary contractile protein
expression and increased contractile capacity of airway smooth
muscle [41]. Thus, to determine whether our in vitro findings were
related to increased contractile airway smooth muscle mass 
in vivo, we determined caveolin-1 expression by airway smooth
muscle using guinea pigs subjected to repeated allergen exposure.
As demonstrated in Figure 5A and B, Western analysis of whole
lung indicated that repeated allergen exposures increased cave-
olin-1 expression. The increase in caveolin-1 was due, in part, to
a specific increase in its expression by the airway smooth muscle,
as determined using quantitative immunohistochemistry (Fig. 6A and
B). These data mimic these we have reported for contractile phe-
notype marker proteins [42, 43]. Thus, it appears that increased
caveolin-1 expression is a feature of allergen-induced airway
smooth muscle remodelling in this animal model.
Discussion
This study indicates that caveolin-1 is a marker of the mature,
contractile smooth muscle cell phenotype and is required for con-
tractile protein expression induced by the growth factor TGF-1.
These findings are in line with previous studies indicating that
caveolin-1 expression and caveolae number are highest in airway
and vascular myocytes with a contractile phenotype [6, 49, 50].
Here we reveal that abundant expression of caveolin-1 promotes
phenotype maturation by TGF-1, as demonstrated by our experi-
ments showing that silencing of caveolin-1 expression prevents
TGF-1-induced contractile protein accumulation. This effect was
associated with a reduction in the capacity of TGF-1 to induce the
phosphorylation of 4E-BP1, a downstream effector of PI 3
kinase/Akt signalling that is required for contractile phenotype
maturation and cellular hypertrophy [48]. Finally, we demonstrate
that caveolin-1 expression is increased in the bronchial smooth
muscle bundle of guinea pigs after repeated allergen exposures.
Collectively, this indicates that caveolin-1 plays a key regulatory
role in contractile phenotype maturation of airway smooth muscle.
This mechanism may contribute to increased airway smooth mus-
cle contractility associated with asthma, and more broadly in
hyperconstrictive disorders of hollow organs.
It appears that caveolin-1 plays several key roles in smooth
muscle contraction and contractile phenotype maturation, and is a
determinant of functional characteristics of myocytes. First, as
demonstrated in this study, increased caveolin-1 expression sub-
serves acquisition of a mature, contractile phenotype that is char-
acterized by increased expression of contractile and contraction
regulatory proteins (e.g. sm--actin, calponin). Second, via its
caveolin scaffolding domain, caveolin-1 plays a facilitating role in
excitation contraction coupling by enhancing Ca2 mobilization in
response to contractile agonists [7, 8, 21, 22, 24, 25]. This facili-
tatory role is likely associated with the ability of caveolin-1 to
recruit and organize Gq proteins, ion channels, Ca2 regulatory
molecules and signalling effectors such as phospholipase C in
caveolae [51]. Third, via its WW domain, caveolin-1 connects to
the dystrophin-dystroglycan complex, which is expressed by con-
tractile myocytes, allowing interaction with the actin cytoskeleton
[12–14]. This interaction could play a structural role, by support-
ing the formation of the characteristic  shape of caveolae, and a
functional role by spatially organizing receptors and signalling
effectors of contraction with intracellular Ca2 stores in the
sarcoplasmatic reticulum and mitochondria [12, 14, 52, 53]. In
parallel, caveolin-1 prevents the activity of proliferative phenotype
myocytes, as it represses the activity of RTKs and non-RTKs that
induce myocyte proliferation and are sequestered in myocyte
Fig. 5 Caveolin-1 expression is increased in the lungs of allergen chal-
lenged guinea pigs. Ovalbumin sensitized guinea pigs were challenged
using ovalbumin once a week for 12 weeks. Twenty-four hours after the
last allergen exposure, lung tissue was collected for further analyses. (A)
Whole lung expression of caveolin-1 was determined using Western blot-
ting for caveolin-1 or -actin to correct for small differences in protein
loading. Densitometric analysis shown in (B) indicates increased caveolin-
1 expression after allergen exposures. Densitometric data shown are the
means 	 S.E. of seven saline and six ovalbumin challenged animals.
Differences between data were analysed by a two-tailed Student’s t-test for
unpaired observations; *P 
 0.05.
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caveolae [6, 16, 19, 54]. This repressive role of caveolin-1 is
reversed by RTK mitogens that induce caveolin-1 phosphorylation
and trafficking of the activated RTK to non-caveolae membrane
where activation of the p42/p44 MAP kinase cascade is achieved
[6, 20]. The repressive role of caveolin-1 in myocyte proliferation
is further illustrated by studies that show reduced expression of
caveolin-1 is a feature of proliferating smooth muscle cells and
that experimental siRNA knockdown of caveolin-1 is sufficient for
the induction of smooth muscle cell proliferation and spontaneous
p42/p44 MAP kinase activation [6, 20]. In contrast, ectopic over-
expression of caveolin-1 silences mitogen responses and induces
cell cycle arrest [54]. Collectively, the results of this study and 
previous studies indicate that caveolin-1 is not only a marker of
myocyte phenotype but also a key determinant of the phenotypic
state of the smooth muscle and in the functions that are associ-
ated with it.
Despite these findings caveolin-1 knockout mice do not lack
expression of smooth muscle in the airways or in other organs and,
although physiological differences from genetic controls in the
lungs and cardiovascular system do exist, they do not suffer from
major defects in smooth muscle contraction or intrinsic contractile
regulation [23]. Species differences are not likely to account for
these effects, as caveolin-1 induction in contractile phenotype
myocytes is a feature observed in both human and canine airway
smooth muscle cells in the current study, and is also seen in rat
arterial smooth muscle [49, 50]. Apparently, smooth muscle differ-
entiation during development is not affected in caveolin-1 knockout
mice, which suggests that not all growth factors involved in
smooth muscle differentiation and maturation require the presence
of caveolin-1 for their effects on smooth muscle specific gene
expression. A similar discrepancy exists for the role of caveolin-1
in calcium handling and contraction as disruption of caveolae or
Fig. 6 Increased caveolin-1 expression
in the airway smooth muscle bundle of
allergen challenged guinea pigs.
Ovalbumin sensitized guinea pigs were
challenged using ovalbumin once a
week for 12 weeks. Twenty-four hours
after the last allergen exposure, lung
tissue was collected for further analy-
ses. (A) Airway smooth muscle expres-
sion of caveolin-1 was determined
using immunohistochemical analysis
for caveolin-1 which showed a clear
positive staining within the airway
smooth muscle bundle. Airway smooth
muscle bundles in sections of saline
challenged animals or ovalbumin chal-
lenged animals were then digitally pho-
tographed and caveolin-1 intensity was
quantified. Densitometric data shown in
(B) are the means 	 S.E. of five saline
and five ovalbumin challenged animals.
Inflammatory cells within the muscle
bundle were excluded from the quan-
tification procedure. Differences
between data were analysed by a two-
tailed Student’s t-test for unpaired
observations; *P 
 0.05.
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knockdown of caveolin-1 reduces muscarinic receptor mediated
calcium mobilization in airway smooth muscle cells [7], whereas
contraction of tracheal smooth muscle strips of caveolin-1 knock-
out mice in response to cholinergic stimulation is not reduced
(Halayko et al., unpublished observations). It appears therefore that
knockout mice functionally compensate for the lack of caveolin-1,
or the role of caveolin-1 in smooth muscle phenotype and function
in smooth muscle cells is highly species or context specific.
Our results indicate a requirement for caveolin-1 in TGF-1
induced contractile protein accumulation in airway smooth mus-
cle. This appears to contrast to previous studies that show cave-
olin-1 is an inhibitor of TGF-1 signalling by inhibiting the activity
of the TGF-1 type I receptor and Smad2 signalling [55]. Also,
caveolin-1 knockout mice have an elevated bronchoalveolar lavage
fluid expression of TGF-1, and have fibrotic lungs and airways
[56]. However, although caveolin-1 inhibits certain aspects of
TGF-1 signalling, more recent studies indicate that regulation of
TGF-1 signalling by caveolin-1 is, in fact, pathway specific. As
such, caveolin-1 inhibits TGF-1 induced Smad3 phosphorylation
in human dermal fibroblasts, but facilitates TGF-1 induced sig-
nalling to the PI 3 kinase/Akt pathway in the same cells [57].
Moreover, although TGF-1 induced Smad2/3 phosphorylation is
maintained in primary rat mesangial cells treated with cholesterol
depleting agents and in murine caveolin-1 knockout mesangial
cells, signalling to RhoA in both cell systems is completely abro-
gated [58]. This illustrates that caveolin-1 plays key roles (both
facilitating and repressive) in directing TGF-1 signalling to spe-
cific intracellular pathways. Our results indicate that caveolin-1 is
required for TGF-1 induced signalling to 4E-BP1, a downstream
target of the PI 3 kinase/Akt signalling pathway. Clearly, the role of
caveolin-1 in TGF-1 signalling is complex and future mechanistic
studies are needed to clarify this differential signalling in more
detail. The key role of caveolin-1 in TGF-1 signalling suggests
that aberrant expression of caveolin-1 protein may contribute to
structural remodelling and disease pathogenesis. Indeed, a strong
reduction of caveolin-1 expression has been observed in idio-
pathic pulmonary fibrosis, a progressive fibrotic disorder of the
lung [59]. Caveolin-1 expression is particularly reduced within the
fibrotic lesions, and appears to facilitate fibroblast proliferation. A
reduction in the pulmonary expression of caveolin-1 is also
observed in patients suffering from pulmonary hypertension,
although interestingly, in this disease the aberrant caveolin-1
expression profile appears strongly cell type specific [60, 61].
Although caveolin-1 expression is reduced in the whole lung
homogenate and within the plexiform vascular lesions, caveolin-1
abundance within the contractile smooth muscle layer is actually
enhanced. Enhanced smooth muscle expression of caveolin-1
may contribute to increased vascular resistance by facilitating
Ca2 mobilization [61], and, as the results from the present study
suggest, contractile protein expression by the myocyte.
Airway smooth muscle contributes to disease pathogenesis in
obstructive airways diseases such as asthma and COPD [1].
Studies on the stereology, phenotype and function of airway
smooth muscle in these diseases reveal an increased smooth
muscle mass, particularly in asthma, that is accompanied by an
increased contractile function of the muscle and, at least in
asthma, by increased expression of contractile phenotype markers
and increased Ca2 mobilization [29, 30, 62–67]. We used a
guinea pig model of asthma to determine caveolin-1 expression
within the bronchial smooth muscle bundle after repeated allergen
exposures. Remodelling of airway smooth muscle in this model is
characterized by an increase in smooth muscle mass, myocyte
sm-MHC expression and smooth muscle contractility [43]. Our
results indicate that caveolin-1 expression by airway smooth mus-
cle is indeed increased as a result of repeated allergen exposures,
which may contribute to smooth muscle maturation as our in vitro
studies using human airway smooth muscle indicate.
In conclusion, the results from our study indicate that caveolin-1
is a marker of the contractile airway smooth muscle phenotype
that is necessary for contractile protein accumulation by TGF-1.
Caveolin-1 appears to function, in part, by directing signalling via
PI3 kinase to 4E-BP1 phosphorylation which is essential for con-
tractile phenotype marker expression. Increased airway smooth
muscle expression of caveolin-1 was also a feature of allergen
challenged guinea pigs. Collectively, we identify a novel function
for caveolin-1 in regulating airway smooth muscle contractile phe-
notype maturation.
Acknowledgements
This work was supported by a Marie Curie Outgoing International
Fellowship from the European Community to R.G. (008823). Operating
funds for this work (to A.J.H.) were supported by a grant from the
Canadian Institutes of Health Research, and in part by the Canada
Foundation for Innovation, and the Canada Research Chairs Program.
A.J.H. holds a Canada Research Chair in Airway Cell and Molecular Biology.
Conflict of interest
The authors confirm that there are no conflicts of interest.
References
1. An SS, Bai TR, Bates JH, et al. Airway
smooth muscle dynamics: a common
pathway of airway obstruction in asthma.
Eur Respir J. 2007; 29: 834–60.
2. Halayko AJ, Solway J. Molecular mecha-
nisms of phenotypic plasticity in smooth
muscle cells. J Appl Physiol. 2001; 90:
358–68.
3. Halayko AJ, Tran T, Ji SY, et al. Airway
smooth muscle phenotype and function:
interactions with current asthma therapies.
Curr Drug Targets. 2006; 7: 525–40.
J. Cell. Mol. Med. Vol 15, No 11, 2011
2441© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
4. Halayko AJ, Tran T, Gosens R. Phenotype
and functional plasticity of airway smooth
muscle: role of caveolae and caveolins.
Proc Am Thorac Soc. 2008; 5: 80–8.
5. Darby PJ, Kwan CY, Daniel EE. Caveolae
from canine airway smooth muscle con-
tain the necessary components for a role
in Ca(2) handling. Am J Physiol Lung
Cell Mol Physiol. 2000; 279: L1226–35.
6. Gosens R, Stelmack GL, Dueck G, et al.
Role of caveolin-1 in p42/p44 MAP kinase
activation and proliferation of human air-
way smooth muscle. Am J Physiol Lung
Cell Mol Physiol. 2006; 291: L523–34.
7. Gosens R, Stelmack GL, Dueck G, et al.
Caveolae facilitate muscarinic receptor-
mediated intracellular Ca2 mobilization
and contraction in airway smooth muscle.
Am J Physiol Lung Cell Mol Physiol. 2007;
293: L1406–18.
8. Prakash YS, Thompson MA, Vaa B, et al.
Caveolins and intracellular calcium regula-
tion in human airway smooth muscle. Am
J Physiol Lung Cell Mol Physiol. 2007;
293: L1118–26.
9. Gosens R, Mutawe M, Martin S, et al.
Caveolae and caveolins in the respiratory
system. Curr Mol Med. 2008; 8: 741–53.
10. Hill MM, Bastiani M, Luetterforst R, 
et al. PTRF-Cavin, a conserved cytoplas-
mic protein required for caveola formation
and function. Cell. 2008; 132: 113–24.
11. Bastiani M, Liu L, Hill MM, et al.
MURC/Cavin-4 and cavin family members
form tissue-specific caveolar complexes. 
J Cell Biol. 2009; 185: 1259–73.
12. Halayko AJ, Stelmack GL. The associa-
tion of caveolae, actin, and the dystrophin-
glycoprotein complex: a role in smooth
muscle phenotype and function? Can J
Physiol Pharmacol. 2005; 83: 877–91.
13. Sotgia F, Lee JK, Das K, et al. Caveolin-3
directly interacts with the C-terminal tail of
beta -dystroglycan. Identification of a cen-
tral WW-like domain within caveolin family
members. J Biol Chem. 2000; 275:
38048–58.
14. Sharma P, Tran T, Stelmack GL, et al.
Expression of the dystrophin-glycoprotein
complex is a marker for human airway
smooth muscle phenotype maturation. Am
J Physiol Lung Cell Mol Physiol. 2008;
294: L57–68.
15. Sharma P, Ghavami S, Stelmack GL, 
et al. beta-Dystroglycan binds caveolin-1
in smooth muscle: a functional role in
caveolae distribution and Ca2 release. J
Cell Sci. 2010; 123: 3061–70.
16. Couet J, Sargiacomo M, Lisanti MP.
Interaction of a receptor tyrosine kinase,
EGF-R, with caveolins. Caveolin binding
negatively regulates tyrosine and
serine/threonine kinase activities. J Biol
Chem. 1997; 272: 30429–38.
17. Liu P, Ying Y, Ko YG, et al. Localization of
platelet-derived growth factor-stimulated
phosphorylation cascade to caveolae. J
Biol Chem. 1996; 271: 10299–303.
18. Rothberg KG, Heuser JE, Donzell WC, 
et al. Caveolin, a protein component of
caveolae membrane coats. Cell. 1992; 68:
673–82.
19. Yamamoto M, Toya Y, Jensen RA, et al.
Caveolin is an inhibitor of platelet-derived
growth factor receptor signaling. Exp Cell
Res. 1999; 247: 380–8.
20. Gosens R, Dueck G, Gerthoffer WT, et al.
p42/p44 MAP kinase activation is localized
to caveolae-free membrane domains in
airway smooth muscle. Am J Physiol Lung
Cell Mol Physiol. 2007; 292: L1163–72.
21. Daniel EE, El-Yazbi A, Cho WJ. Caveolae
and calcium handling, a review and a
hypothesis. J Cell Mol Med. 2006; 10:
529–44.
22. Daniel EE, Eteraf T, Sommer B, et al. The
role of caveolae and caveolin 1 in calcium
handling in pacing and contraction of
mouse intestine. J Cell Mol Med. 2009; 13:
352–64.
23. Drab M, Verkade P, Elger M, et al. Loss
of caveolae, vascular dysfunction, and
pulmonary defects in caveolin-1 gene-
disrupted mice. Science. 2001; 293:
2449–52.
24. Dreja K, Voldstedlund M, Vinten J, et al.
Cholesterol depletion disrupts caveolae
and differentially impairs agonist-induced
arterial contraction. Arterioscler Thromb
Vasc Biol. 2002; 22: 1267–72.
25. Je HD, Gallant C, Leavis PC, et al.
Caveolin-1 regulates contractility in differ-
entiated vascular smooth muscle. Am J
Physiol Heart Circ Physiol. 2004; 286:
H91–8.
26. Shakirova Y, Mori M, Ekman M, et al.
Human urinary bladder smooth muscle is
dependent on membrane cholesterol for
cholinergic activation. Eur J Pharmacol.
2010; 634: 142–8.
27. Schlenz H, Kummer W, Jositsch G, et al.
Muscarinic receptor-mediated bron-
choconstriction is coupled to caveolae in
murine airways. Am J Physiol Lung Cell
Mol Physiol. 2009; doi:10.1152/
ajplung.00261.2009.
28. Sommer B, Montano LM, Carbajal V, 
et al. Extraction of membrane cholesterol
disrupts caveolae and impairs serotoner-
gic (5-HT2A) and histaminergic (H1)
responses in bovine airway smooth
muscle: role of Rho-kinase. Can J Physiol
Pharmacol. 2009; 87: 180–95.
29. Benayoun L, Druilhe A, Dombret MC, 
et al. Airway structural alterations selec-
tively associated with severe asthma. Am
J Respir Crit Care Med. 2003; 167:
1360–8.
30. Ma X, Cheng Z, Kong H, et al. Changes in
biophysical and biochemical properties of
single bronchial smooth muscle cells from
asthmatic subjects. Am J Physiol Lung
Cell Mol Physiol. 2002; 283: L1181–9.
31. Dekkers BG, Maarsingh H, Meurs H, 
et al. Airway structural components drive
airway smooth muscle remodeling in
asthma. Proc Am Thorac Soc. 2009; 6:
683–92.
32. Leguillette R, Laviolette M, Bergeron C,
et al. Myosin, transgelin, and myosin light
chain kinase: expression and function in
asthma. Am J Respir Crit Care Med. 2008;
179: 194–204.
33. Woodruff PG, Dolganov GM, Ferrando RE,
et al. Hyperplasia of smooth muscle in
mild to moderate asthma without changes
in cell size or gene expression. Am J Respir
Crit Care Med. 2004; 169: 1001–6.
34. Halayko AJ, Rector E, Stephens NL.
Airway smooth muscle cell proliferation:
characterization of subpopulations by sen-
sitivity to heparin inhibition. Am J Physiol.
1998; 274: L17–25.
35. Halayko AJ, Stelmack GL, Yamasaki A,
et al. Distribution of phenotypically dis-
parate myocyte subpopulations in airway
smooth muscle. Can J Physiol Pharmacol.
2005; 83: 104–16.
36. Halayko AJ, Camoretti-Mercado B,
Forsythe SM, et al. Divergent differentia-
tion paths in airway smooth muscle cul-
ture: induction of functionally contractile
myocytes. Am J Physiol. 1999; 276:
L197–206.
37. Halayko AJ, Kartha S, Stelmack GL, et al.
Phophatidylinositol-3 kinase/mammalian
target of rapamycin/p70S6K regulates
contractile protein accumulation in airway
myocyte differentiation. Am J Respir Cell
Mol Biol. 2004; 31: 266–75.
38. Tran T, Ens-Blackie K, Rector ES, et al.
Laminin-binding integrin {alpha}7 is
required for contractile phenotype expres-
sion by human airway myocyte. Am J
Respir Cell Mol Biol. 2007; 37: 668–80.
39. Ghavami S, Mutawe MM, Hauff K, et al.
Statin-triggered cell death in primary
human lung mesenchymal cells involves
p53-PUMA and release of Smac and Omi
2442 © 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
but not cytochrome c. Biochim Biophys
Acta. 2010; 1803: 452–67.
40. Tran J, Kung SK. Lentiviral vectors medi-
ate stable and efficient gene delivery into
primary murine natural killer cells. Mol
Ther. 2007; 15: 1331–9.
41. Meurs H, Santing RE, Remie R, et al. A
guinea pig model of acute and chronic
asthma using permanently instrumented
and unrestrained animals. Nat Protoc.
2006; 1: 840–7.
42. Bos IS, Gosens R, Zuidhof AB, et al.
Inhibition of allergen-induced airway
remodelling by tiotropium and budes-
onide: a comparison. Eur Respir J. 2007;
30: 653–61.
43. Gosens R, Bos IS, Zaagsma J, et al.
Protective effects of tiotropium bromide in
the progression of airway smooth muscle
remodeling. Am J Respir Crit Care Med.
2005; 171: 1096–102.
44. Halayko AJ, Salari H, Ma X, et al.
Markers of airway smooth muscle cell
phenotype. Am J Physiol. 1996; 270:
L1040–51.
45. Goldsmith AM, Bentley JK, Zhou L, et al.
Transforming growth factor-beta induces
airway smooth muscle hypertrophy. Am J
Respir Cell Mol Biol. 2006; 34: 247–54.
46. Gawaziuk JP, X, Sheikh F, et al.
Transforming growth factor-beta as a dif-
ferentiating factor for cultured smooth
muscle cells. Eur Respir J. 2007; 30:
643–52.
47. Zhou L, Li J, Goldsmith AM, et al. Human
bronchial smooth muscle cell lines show a
hypertrophic phenotype typical of severe
asthma. Am J Respir Crit Care Med. 2004;
169: 703–11.
48. Zhou L, Goldsmith AM, Bentley JK, et al.
4E-binding protein phosphorylation and
eukaryotic initiation factor-4E release are
required for airway smooth muscle hyper-
trophy. Am J Respir Cell Mol Biol. 2005;
33: 195–202.
49. Thyberg J, Roy J, Tran PK, et al.
Expression of caveolae on the surface of
rat arterial smooth muscle cells is depend-
ent on the phenotypic state of the cells.
Lab Invest. 1997; 77: 93–101.
50. Thyberg J. Differences in caveolae dynam-
ics in vascular smooth muscle cells of dif-
ferent phenotypes. Lab Invest. 2000; 80:
915–29.
51. Isshiki M, Anderson RG. Function of cave-
olae in Ca2 entry and Ca2-dependent
signal transduction. Traffic. 2003; 4:
717–23.
52. Gherghiceanu M, Popescu LM. Caveolar
nanospaces in smooth muscle cells. J Cell
Mol Med. 2006; 10: 519–28.
53. Popescu LM, Gherghiceanu M,
Mandache E, et al. Caveolae in smooth
muscles: nanocontacts. J Cell Mol Med.
2006; 10: 960–90.
54. Peterson TE, Guicciardi ME, Gulati R, 
et al. Caveolin-1 can regulate vascular
smooth muscle cell fate by switching
platelet-derived growth factor signaling
from a proliferative to an apoptotic path-
way. Arterioscler Thromb Vasc Biol. 2003;
23: 1521–7.
55. Razani B, Zhang XL, Bitzer M, et al.
Caveolin-1 regulates transforming growth
factor (TGF)-beta/SMAD signaling through
an interaction with the TGF-beta type I
receptor. J Biol Chem. 2001; 276:
6727–38.
56. Le Saux CJ, Teeters K, Miyasato SK, et
al. Down-regulation of caveolin-1, an
inhibitor of transforming growth factor-
beta signaling, in acute allergen-induced
airway remodeling. J Biol Chem. 2008;
283: 5760–8.
57. Kim S, Lee Y, Seo JE, et al. Caveolin-1
increases basal and TGF-beta1-induced
expression of type I procollagen through
PI-3 kinase/Akt/mTOR pathway in human
dermal fibroblasts. Cell Signal. 2008; 20:
1313–9.
58. Peng F, Zhang B, Wu D, et al. TGF{beta}-
Induced RhoA Activation and Fibronectin
Production in Mesangial Cells Requires
Caveolae. Am J Physiol Renal Physiol.
2008; 295: F153–64.
59. Wang XM, Zhang Y, Kim HP, et al.
Caveolin-1: a critical regulator of lung
fibrosis in idiopathic pulmonary fibrosis. J
Exp Med. 2006; 203: 2895–906.
60. Achcar RO, Demura Y, Rai PR, et al. Loss
of caveolin and heme oxygenase expres-
sion in severe pulmonary hypertension.
Chest. 2006; 129: 696–705.
61. Patel HH, Zhang S, Murray F, et al.
Increased smooth muscle cell expression
of caveolin-1 and caveolae contribute to the
pathophysiology of idiopathic pulmonary arte-
rial hypertension. FASEB J. 2007; 21: 2970–9.
62. Hogg JC, Chu F, Utokaparch S, et al. The
nature of small-airway obstruction in
chronic obstructive pulmonary disease. 
N Engl J Med. 2004; 350: 2645–53.
63. Jeffery PK. Remodeling and inflammation
of bronchi in asthma and chronic obstruc-
tive pulmonary disease. Proc Am Thorac
Soc. 2004; 1: 176–83.
64. Jiang H, Rao K, Halayko AJ, et al.
Ragweed sensitization-induced increase of
myosin light chain kinase content in canine
airway smooth muscle. Am J Respir Cell
Mol Biol. 1992; 7: 567–73.
65. Jiang H, Rao K, Liu X, et al. Increased
Ca2 and myosin phosphorylation, but
not calmodulin activity in sensitized airway
smooth muscles. Am J Physiol. 1995; 268:
L739–46.
66. Opazo Saez AM, Seow CY, Pare PD.
Peripheral airway smooth muscle mechan-
ics in obstructive airways disease. Am J
Respir Crit Care Med. 2000; 161: 910–7.
67. Trian T, Benard G, Begueret H, et al.
Bronchial smooth muscle remodeling
involves calcium-dependent enhanced
mitochondrial biogenesis in asthma. J Exp
Med. 2007; 204: 3173–81.
